Table 1
Histologic characteristics of the patients with endometrioid endometrial carcinoma (N = 211) and non-endometrioid endometrial carcinoma (N = 16)
| Histologic parameter | Endometrioid endometrial carcinoma | Non-endometrioid endometrial carcinoma | p* |
|---|---|---|---|
| Tumour differentiation | < 0.001 | ||
| G1 | 125 (59.2%) | 2 (13.3%) | |
| G2 | 63 (29.9%) | 4 (26.6%) | |
| G3 | 23 (10.9%) | 9 (60.0%) | |
| Myometrial invasion | |||
| none | 8 (3.8%) | 1 (6.3%) | 0.888 |
| less than ½ | 123 (58.3%) | 9 (56.2%) | |
| more than ½ | 80 (37.9%) | 6 (37.5%) | |
| 2009 FIGO stage | |||
| IA | 114 (54.0%) | 7 (43.8%) | 0.025 |
| IB | 54 (25.6%) | 1 (6.3%) | |
| II | 14 (6.6%) | 2 (12.5%) | |
| IIIA | 7 (3.3%) | 1 (6.3%) | |
| IIIB | 5 (2.4%) | 0 (0.0%) | |
| IIIC1 | 11 (4.7%) | 2 (12.5%) | |
| IIIC2 | 0 (0.0%) | 0 (0.0%) | |
| IVA | 1 (0.5%) | 1 (6.3%) | |
| IVB | 5 (2.4%) | 2 (12.5%) |
Table 2
Histologic characteristics of the patients with endometrial carcinoma (N = 227) who were diagnosed with hysteroscopy (HSC) or dilatation and curettage (D&C)
| Histologic parameter | HSC (N = 144) | D&C (N = 83) | P value | |
|---|---|---|---|---|
| Histologic type | ||||
| endometrioid adenocarcinoma | 137 (95.1%) | 74 (89.2%) | 0.090* | |
| non-endometrioid adenocarcinoma | 7 (4.9%) | 9 (10.8%) | ||
| Tumour differentiation | ||||
| G1 | 90 (62.5%) | 37 (45.1%) | 0.012* | |
| G2 | 40 (27.8%) | 27 (32.9%) | ||
| G3 | 14 (9.7%) | 18 (22.0%) | ||
| Myometrial invasion | ||||
| none | 5 (3.5%) | 4 (4.8%) | 0.726* | |
| less than ½ | 82 (56.9%) | 50 (60.2%) | ||
| more than ½ | 57 (39.6%) | 29 (34.9%) | ||
| Lymphovascular invasion | ||||
| present | 20 (13.9%) | 14 (16.9%) | 0.545* | |
| absent | 124 (86.1%) | 69 (83.1%) | ||
| 2009 FIGO stage | ||||
| IA | 75 (52.1%) | 46 (55.4%) | ||
| IB | 42 (29.2%) | 13 (15.7%) | ||
| II | 10 (6.9%) | 6 (7.2%) | ||
| IIIA | 1 (0.7%) | 7 (8.4%) | ||
| IIIB | 3 (2.1%) | 2 (2.4%) | 0.040* | |
| IIIC1 | 9 (6.3%) | 4 (4.8%) | ||
| IIIC2 | 0 (0.0%) | 0 (0.0%) | ||
| IVA | 1 (0.7%) | 1 (1.2%) | ||
| IVB | 3 (2.1%) | 4 (4.8%) | ||
| Peritoneal cytology positive or suspicious negative | 19 (13.2%) 125 (86.8%) | 10 (12.0%) 73 (88.0%) | 0.803* | |
| Time from diagnosis to operation (days) | 35.8 ± 13.8 | 32.8 ± 15.4 | 0.140** |
Table 3
Histologic characteristics of the patients with stage 1 endometrial carcinoma (N = 187) who were diagnosed with hysteroscopy (HSC) or dilatation and curettage (D&C)
| Stage 1 | HSC (N = 117) | D&C (N = 59) | P value |
|---|---|---|---|
| Histologic type | |||
| endometrioid adenocarcinoma | 112 (95.7%) | 56 (94.9%) | 0.807* |
| non-endometrioid adenocarcinoma | 5 (4.3%) | 3 (5.1%) | |
| Tumour differentiation | |||
| G1 | 75 (64.1%) | 29 (49.2%) | 0.156* |
| G2 | 32 (27.4%) | 22 (37.3%) | |
| G3 | 10 (8.5%) | 8 (13.5%) | |
| Myometrial invasion | |||
| none | 5 (4.3%) | 3 (5.1%) | 0.079* |
| less than ½ | 71 (60.7%) | 45 (76.2%) | |
| more than ½ | 41 (35.0%) | 11 (18.6%) | |
| Peritoneal cytology positive or suspicious negative | 15 (12.8%) 102 (87.2%) | 2 (3.4%) 57 (96.6%) | 0.046* |
| Time from diagnosis to operation (days) | 35.6 ± 14.0 | 33.1 ± 12.7 | 0.255** |